Evidence for antifibrotic incretin-independent effects of the DPP-4 inhibitor linagliptin
Evidence for antifibrotic incretin-independent effects of the DPP-4 inhibitor linagliptin
About this item
Full title
Author / Creator
Publisher
United States: Elsevier Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: Elsevier Inc
Subjects
More information
Scope and Contents
Contents
Among gliptins, linagliptin is unique, because decreased glomerular filtration rate does not require dose reduction. Linagliptin was originally developed to lower blood glucose by inhibiting dipeptidyl peptidase-4 (DPP-4). However, DPP-4 has numerous additional substrates, and thus gliptins possess a vast range of additional off-target effects. Shi...
Alternative Titles
Full title
Evidence for antifibrotic incretin-independent effects of the DPP-4 inhibitor linagliptin
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1708904011
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1708904011
Other Identifiers
ISSN
0085-2538
E-ISSN
1523-1755
DOI
10.1038/ki.2015.175
